<DOC>
	<DOCNO>NCT01227655</DOCNO>
	<brief_summary>Parkinson 's disease ( PD ) neurodegenerative disorder unknown aetiology estimate incidence 4.5-16/100,000 persons/year . BIA 9-1067 currently develop BIAL ( Portela &amp; CÂª , S.A . ) use addition L-DOPA ( Levodopa ) /carbidopa L-DOPA ( Levodopa ) / preparation PD patient . Promising result obtain BIA 9-1067 previous study .</brief_summary>
	<brief_title>Efficacy Safety BIA 9-1067 Idiopathic Parkinson 's Disease Patients .</brief_title>
	<detailed_description>This study aim demonstrate efficacy safety BIA 9-1067 used addition L-DOPA/DDCI control `` wearing-off '' phenomenon patient PD . DDCI ( DOPA decarboxylase inhibitor ) : benserazide carbidopa</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Dopa Decarboxylase</mesh_term>
	<mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
	<criteria>1 . Able comprehend willing sign inform consent form . 2 . Male female subject 30 83 year old , inclusive . 3 . Diagnosed idiopathic PD accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria least 3 year . 4 . Disease severity Stages IIII ( modify Hoehn &amp; Yahr stag ) ON . 5 . Treated LDOPA/DDCI least 1 year clear clinical improvement . 6 . Treated 3 8 daily dos LDOPA/DDCI , include slowrelease formulation . 7 . On stable regimen LDOPA/DDCI antiPD drug least 4 week screen . 8 . Signs `` wearingoff '' phenomenon ( endofdose deterioration ) minimum 4 week screen average total daily OFF time awake least 1.5 hour , exclude early morning prefirst dose OFF , despite optimal antiPD therapy ( base investigator 's judgment . 1 . Nonidiopathic PD ( atypical parkinsonism , secondary [ acquire symptomatic ] parkinsonism , Parkinsonplus syndrome ) . 2 . Dyskinesia disability score &gt; 3 Unified Parkinson 's Disease Rating Scale UPDRS ) Subsection IV A , item 33 . 3 . Severe and/or unpredictable OFF period . 4 . Treatment prohibited medication : entacapone , tolcapone , neuroleptic , venlafaxine , MAO inhibitor ( except selegiline 10 mg/day oral formulation 1.25 mg/day buccal absorption formulation rasagiline 1mg/day ) , antiemetic antidopaminergic action ( except domperidone ) within month screening . 5 . Treatment apomorphine within month screen likely need time study . 6 . Dosage change concomitant antiPD medication within 4 week screen . 7 . Previous plan ( entire study duration , include OL period ) deep brain stimulation . 8 . Previous stereotactic surgery ( e.g . pallidotomy , thalamotomy ) PD plan stereotactic surgery study period . 9 . Any investigational medicinal product within 3 month ( within 5 halflives , whichever long ) screening . 10 . Any medical condition might place subject increase risk interfere assessment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>83 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>PD</keyword>
	<keyword>Wearing-off</keyword>
	<keyword>Levodopa/DDCI</keyword>
</DOC>